MoonLake Immunotherapeutics (MLTX) Q3 2026 earnings summary

Executive summary

• Q3 2026 net loss was $79.5M; operating expenses rose 11.8% YoY to $79.9M, largely reflecting higher R&D spending.

• September 30 liquidity totaled $498.5M in cash, cash equivalents and short-term marketable debt securities, supporting a projected runway through mid-2028.

• Submitted an FDA BLA for sonelokimab (SLK) for moderate-to-severe HS in adults and patients aged 12 and older; a U.S. launch is targeted for H2 2027, subject to approval.

Financial highlights

• Q3 operating expenses were $79.9M, up 11.8% YoY; net loss was $79.5M versus $70.7M.

• Q3 R&D expense was $68.9M, up 13.6% YoY and from $50.2M in Q2, primarily due to an accrued milestone license fee; G&A was $11.0M, up 1.7% YoY and down from $11.4M in Q2.

• 9M operating expenses increased 17.8% YoY to $211.5M; net loss was $211.1M versus $167.3M.

• 9M operating cash outflow was $185.2M versus $137.2M; financing provided $292.2M, primarily from equity offerings and loan proceeds.

• No product-sales revenue; Q3 operating loss was $79.9M and net loss was $79.5M, versus $61.7M and $61.8M in Q2, respectively.

Outlook and guidance

• Current operating plan projects funding for operations and capital expenditures through mid-2028; substantial expenses and operating losses are expected for at least two years.

• FDA BLA acceptance decision was expected by end-November 2026, with PDUFA date allocation and Priority Review decision expected by mid-December; U.S. launch is targeted for H2 2027 if approved.

• VELA-TEEN trial completion is expected in Q4 2026, with final topline results in Q1 2027; year-one VELA OLE data are expected in H2 2027.

• IZAR-1 Week 52 results are expected in Q2 2027; IZAR-2 Week 16 and Week 52 results in Q1 and Q4 2027, respectively; P-OLARIS results are expected in early 2027.

• Phase 3 NOVA enrollment for PPP is expected to begin in November 2026; its primary endpoint is PPP-IGA 0/1 with at least a 2-point improvement at Week 12.